Patrick Soon-Shiong
MB ChB MMed
Executive Chairman
👥Biography 个人简介
Patrick Soon-Shiong developed nab-paclitaxel (Abraxane) — a pioneering albumin-bound nanoparticle formulation of paclitaxel that improved tolerability and activity compared to cremophor-solubilized paclitaxel. Abraxane received FDA approval for breast cancer, NSCLC, and pancreatic cancer (in combination with gemcitabine), and represented one of the first nanomedicine oncology approvals to achieve widespread clinical use.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Patrick Soon-Shiong 的研究动态
Follow Patrick Soon-Shiong's research updates
留下邮箱，当我们发布与 Patrick Soon-Shiong（ImmunityBio）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment